clinical trial · NCT06151288
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Pneumococcal Vaccines31 valent pneumococcal conjugate vaccine20 valent pneumococcal conjugate vaccine
brief summary
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
started
Nov 8, 2023
primary completion
Jul 17, 2024
completion
Jul 17, 2024
last updated
Jul 28, 2025
official title
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Active-Controlled, Parallel-Group, Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Healthy Adults Aged 50 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol